Minimally invasive open surgery (MIOS) for clinical stage I lung cancer: diversity in minimally invasive procedures.

Abstract

Many thoracic surgeons have tried to make lung cancer surgery less invasive. Among the minimally invasive approaches that are currently available, it is controversial which is optimal. Minimally invasive open surgery, i.e. hybrid video-assisted thoracic surgery, has been adopted for lung cancer surgery at our institute. The objective of this study was to evaluate minimally invasive open surgery in terms of perioperative outcomes over the most recent 5years. Between 2015 and 2019, 2738 patients underwent pulmonary resection for lung cancer at National Cancer Center Hospital, Japan. Among them, 2174 patients with clinical stage I lung cancer who underwent minimally invasive open surgery were included. Several perioperative parameters were evaluated. The patients consisted of 1092 men (50.2%) and 1082 women (49.8%). Lobectomy was performed in 1255 patients (57.7%), segmentectomy in 603 (27.7%) and wide wedge resection in 316 (14.5%). Median blood loss was 30ml (interquartile range: 15-57ml) for lobectomy, 17ml (interquartile range: 10-31ml) for segmentectomy and 5ml (interquartile range: 2-10ml) for wide wedge resection. Median operative time was 120min (interquartile range: 104-139min) for lobectomy, 109min (interquartile range: 98-123min) for segmentectomy and 59min (interquartile range: 48-76min) for wide wedge resection. Median length of postoperative hospital stay was 4days (interquartile range: 3-5days). The 30-day mortality rate was 0.08% for lobectomy, 0.17% for segmentectomy and 0.00% for wide wedge resection. Minimally invasive open surgery for clinical stage I lung cancer is a feasible approach with a low mortality and a short hospital stay. Oncological outcomes need to be investigated.